Form 4 for LRMR Larimar Therapeutics, Inc.
Accepted 2026-01-27 00:00:00 ET · period of report 2026-01-26 · accession 0001193125-26-024833 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-27 | 2026-01-26 | LRMR | Shankar Gopi | Chief Development Off | A - Grant | $0.00 | +25.6K | 76.4K | +50% | $0 |
| D | 2026-01-27 | 2026-01-26 | LRMR | Shankar Gopi | Chief Development Off | A - Grant | $0.00 | +153.8K | 153.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-26 | A | A | 25,637 | $0.00 | 76,443 | D | — | — | (F1) Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-01-26 | A | A | 153,822 | $0.00 | 153,822 | D | $3.60 · — to 2036-01-26 | 153,822 Common Stock | (F2) The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. |